Rafael Holdings, Inc. (RFL)
NYSE: RFL · Real-Time Price · USD
1.090
+0.020 (1.87%)
Nov 5, 2026, 11:04 AM EST - Market open
Rafael Holdings Employees
As of July 31, 2025, Rafael Holdings had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 8 or 25.81% compared to the previous year. That makes Rafael Holdings the 38,011th largest employer in the world and 5,449th in the United States.
Employees
23
Change (1Y)
-8
Growth (1Y)
-25.81%
Revenue / Employee
$38,000
Profits / Employee
-$1,288,478
Market Cap
56.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jul 31, 2025 | 23 | -8 | -25.81% | 21 | 2 |
| Jul 31, 2024 | 31 | 18 | 138.46% | 28 | 3 |
| Jul 31, 2023 | 13 | -10 | -43.48% | 13 | 0 |
| Jul 31, 2022 | 23 | -39 | -62.90% | 22 | 1 |
| Jul 31, 2021 | 62 | 2 | 3.33% | 51 | 11 |
| Jul 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Altisource Portfolio Solutions | 1,236 |
| Douglas Elliman | 580 |
| Fangdd Network Group | 144 |
| EUDA Health Holdings | 123 |
| J.W. Mays | 26 |
| Seritage Growth Properties | 5 |
RFL News
- 2 days ago - Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - GlobeNewsWire
- 7 days ago - Rafael Holdings Earnings release: Q4 2026 - Filings
- 7 days ago - Rafael Holdings Annual report: Q4 2026 - Filings
- 7 days ago - Rafael Holdings submits New Drug Application to FDA for remibetadex - TheFly
- 7 days ago - Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C - GlobeNewsWire
- 5 weeks ago - Rafael Holdings Transcript: Study result - Transcripts
- 5 weeks ago - Rafael Holdings Press release: Study result - Filings